Brand-Name Pharmaceutical Manufacturing in Canada - Industry Market Research Report

Take Two: Improving the Affordability of Essential Drugs Will Continue to Be a Major Threat to the Industry

Brand-name pharmaceutical manufacturers in Canada have endured strong competitive pressures from generic drugs by innovating its product line and attracting higher demand from Canadians. In response to many brand-name drugs losing their patent protection, many companies have streamlined their operations. By forming networks with public or private companies and academic institutions, brand-name pharmaceutical manufacturers have been able to share research and development costs. This trend has been vital regarding investing in biopharmaceutical development, as exemplified by the rising investment in research and development in pharmaceutical companies. This has proved fruitful amid the COVID-19 pandemic, as companies have partnered together to quickly develop effective vaccines. Efficient vaccine manufacturing has supported revenue, but increasing generic drug usage has offset this trend. Revenue has decreased at a CAGR of 1.9% to $8.0 billion over the five years to 2023. This includes a forecast expansion of 0.7% in 2023 alone, as the economy continues to normalize in the wake of the pandemic.

The Brand-Name Pharmaceutical Manufacturing industry in Canada develops prescription and over-the-counter products used to treat illnesses in humans and animals. Brand-name drugs have patent protection. This industry does not include nutritional supplement or cosmetics manufacturers.

This report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors. Also included are five year industry forecasts, growth rates and an analysis of the industry's key players and their market shares.